Cicatrix
Drug research and approvals for cicatrix: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 130 studies of cicatrix are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 130
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 130 recruiting on ClinicalTrials.gov ↗- Post-Operative Use of FS2 to Mitigate Scarring in Burn PatientsNCT06807021 · Phase 2 / Phase 3 · Birch BioMed Inc · starts Mar 1, 2027
- Pre-marketing Trial to Assess Safety and Efficacy of 'Volumizing Filler Based on Hyaluronic Acid and Recombinant…NCT06336044 · Not applicable · Taumedika s.r.l. · starts Nov 1, 2026
- Disposable Noninvasive Skin Closure for Promoting Postoperative Wound Healing and Preventing Surgical Skin ScarringNCT07849010 · Not applicable · Peking University Third Hospital · starts Oct 8, 2026
- Impact of a Bladder Flap on Cesarean Scar Niche DevelopmentNCT07634679 · Not applicable · Montefiore Medical Center · starts Oct 3, 2026
- SCARFREE-001: Verteporfin for Scar PreventionNCT07488988 · Phase 2 · Odense University Hospital · starts Oct 1, 2026
- Tirzepatide for Treatment of CCCANCT07734870 · Phase 2 · Johns Hopkins University · starts Sep 15, 2026
- CIC101-02-LT is a Long-term Follow-up Study of Participants Treated With TRTP-101 and Will Evaluate the Long-term…NCT07892937 · Not reported · CellinCells · starts Sep 11, 2026
- Topical CBD Scar Healing StudyNCT06129591 · Phase 1 · University of Oklahoma · starts Sep 1, 2026
- Effect of a Probiotic or Postbiotic on Gut Microbiome During Antibiotic TreatmentNCT07594860 · Not applicable · The Archer-Daniels-Midland Company · starts Aug 27, 2026
- Autologous Free Dermal Graft Support in Superior Pedicle Vertical Scar Reduction MammaplastyNCT07657962 · Not reported · Cumhuriyet University Hospital · starts Aug 24, 2026
Drug Pipeline
3 in phase 3, 5 in phase 2, 6 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Onabotulinumtoxina
- Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Urea
- Phase 3 Diagnostic agent
- Putrescine
- Phase 3
- AZX-100
- Phase 2
- Abobotulinumtoxina
- Phase 2 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Enalaprilat anhydrous
- Phase 2 Angiotensin-converting enzyme inhibitor
- Lipoic acid, alpha
- Phase 2
- Trichloroacetic acid
- Phase 2
- Pentamidine
- Phase 1 DNA inhibitor
- Avotermin
- Phase 1
- Ilodecakin
- Phase 1
- Lidocaine
- Early phase 1 Sodium channel alpha subunit blocker
- Racepinephrine
- Early phase 1
- Centella asiatica extract
- Early phase 1
How Its Trials Ended
260 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 52 whose ending is known, 35% met their primary endpoint, 2% missed it and 63% stopped early.
- Completed, result not reported12046%
- Status unknown4919%
- Ongoing3915%
- Stopped: other or unclear249%
- Met its primary endpoint187%
- Stopped: enrollment or feasibility62%
- Stopped: lack of efficacy21%
- Missed its primary endpoint10%
- Stopped: funding10%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA